Kerry Anne Rogers MD

Associate Professor

460 W 10th Ave5th FloorColumbus, OH 43210
Phone+1 614-366-9338
Fax+1 614-293-4812

Dr. Rogers is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rogers' full profile Already have an account?

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2012 - 2015
University of MichiganResidency, Internal Medicine, 2008 - 2011
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2008

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

OH State Medical License 2012 - 2028
MI State Medical License 2008 - 2015
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance Start of enrollment: 2020 Mar 11
WITHDRAWN
PHASE2
Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2021 Mar 18
TERMINATED
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2015 Aug 03
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2

Publications & Presentations

PubMed

Outcomes of patients with chronic lymphocytic leukemia discontinuing covalent Bruton tyrosine kinase inhibitors due to adverse events.
Anthony G Mansour, Ying Huang, J Phillip Pemberton, Aseel Alsouqi, Adam S Kittai
Leukemia. 2026-08-01
Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.
Clive S Zent, Enrico Tiacci, Robert J Kreitman, Tamar Tadmor, Martin S Tallman
Blood. 2026-07-02
Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib.
Shanmugapriya Thangavadivel, Jami Shaffer, Shrilekha Misra, Samon Benrashid, Britten K Gordon
Clinical Cancer Research. 2026-05-01

Abstracts/Posters

Restoring Functional Deficits in Older Adults with Hematologic Malignancy
Kerry A. Rogers, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
LC-Facseq: A Novel Method for Detecting Rare Resistant Clones in Leukemia
Kerry A. Rogers, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity
Kerry A. Rogers, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicent...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

New Combination Therapy Shows Promise in Reducing Lifelong Ibrutinib Use for Chronic Lymphocytic LeukemiaNovember 6th, 2025
Combination Therapy Offers Hope for Ending Lifelong Chronic Lymphocytic Leukemia TreatmentNovember 5th, 2025
Reimbursement Freefall Predicted for Radiation OncologyMarch 19th, 2025